Formulation and Evaluation of Fast Disintegrating Tablet of Eletriptan Hydrobromide

The present study focuses on the formulation and evaluation of fast disintegrating tablets (FDTs) of Eletriptan hydrobromide, an antimigraine agent with poor oral bioavailability due to extensive first-pass metabolism.The aim was to develop a formulation that ensures rapid onset of action by enhancing disintegration time and drug release.Different amounts of superdisintegrants, such as croscarmellose sodium (CCS) and sodium starch glycolate (SSG), were employed.Among the formulations developed, formulation F5, containing SSG and CCS, demonstrated optimal results with a disintegration time of less than 15 seconds, meeting all required physicochemical parameters.In vitro drug release studies showed up to 99.7% release, indicating excellent dissolution characteristics.These findings support the potential of FDTs of Eletriptan hydrobromide as a fast-acting, patient-friendly alternative for the effective management of acute migraine attacks.